Six Flags Entertainment Stock Hits New 52-Week High (SIX)

NEW YORK ( TheStreet) -- Six Flags Entertainment (NYSE: SIX) hit a new 52-week high Friday as it is currently trading at $50.78, above its previous 52-week high of $50.77 with 130,058 shares traded as of 10 a.m. ET. Average volume has been 311,200 shares over the past 30 days.

Six Flags Entertainment has a market cap of $2.7 billion and is part of the services sector and leisure industry. Shares are up 15.3% year to date as of the close of trading on Thursday.

Six Flags Entertainment Corporation owns and operates regional theme, water, and zoological parks. The company's parks offers various selection of state-of-the-art and traditional thrill rides, water attractions, themed areas, concerts and shows, restaurants, game venues, and retail outlets.

TheStreet Ratings rates Six Flags Entertainment as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally poor debt management. You can view the full Six Flags Entertainment Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI